🚀 VC round data is live in beta, check it out!
Oculis Holding Valuation Multiples
Discover revenue and EBITDA valuation multiples for Oculis Holding and similar public comparables like Samsung, Johnson & Johnson, Roche, Siemens and more.
Oculis Holding Overview
About Oculis Holding
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
Founded
2016
HQ
Employees
49
Website
Sectors
Financials (LTM)
Market Cap
—
Oculis Holding Financials
Oculis Holding reported last 12-month revenue of $3M and negative EBITDA of ($110M).
In the same LTM period, Oculis Holding generated $3M in gross profit, ($110M) in EBITDA losses, and had net loss of ($125M).
Revenue (LTM)
Oculis Holding P&L
In the most recent fiscal year, Oculis Holding reported revenue of $2M and EBITDA of ($108M).
Oculis Holding expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $3M | XXX | $2M | XXX | XXX | XXX |
| Gross Profit | $3M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($110M) | XXX | ($108M) | XXX | XXX | XXX |
| EBITDA Margin | (3993%) | XXX | (7038%) | XXX | XXX | XXX |
| EBIT Margin | (3942%) | XXX | (6685%) | XXX | XXX | XXX |
| Net Profit | ($125M) | XXX | ($125M) | XXX | XXX | XXX |
| Net Margin | (4524%) | XXX | (8100%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Oculis Holding Stock Performance
Oculis Holding has current market cap of —.
| Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|
| — | — | XXX | XXX | XXX | — |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialOculis Holding Valuation Multiples
Oculis Holding Financial Valuation Multiples
As of March 30, 2026, Oculis Holding has market cap of —.
Equity research analysts estimate Oculis Holding's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 |
|---|
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Oculis Holding Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Oculis Holding Margins & Growth Rates
Oculis Holding's revenue in the last 12 month grew by 497%.
Oculis Holding's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $2.1M for the same period.
Oculis Holding Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 497% | XXX | 327% | XXX | XXX | XXX |
| EBITDA Margin | (3993%) | XXX | (7038%) | XXX | XXX | XXX |
| EBITDA Growth | 9% | XXX | 8% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $2.1M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1209% | XXX | 2097% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 2838% | XXX | 4749% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 6685% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Oculis Holding Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Samsung | XXX | XXX | XXX | XXX | XXX | XXX |
| Johnson & Johnson | XXX | XXX | XXX | XXX | XXX | XXX |
| Roche | XXX | XXX | XXX | XXX | XXX | XXX |
| Siemens | XXX | XXX | XXX | XXX | XXX | XXX |
| Abbott | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Oculis Holding M&A Activity
Oculis Holding acquired XXX companies to date.
Last acquisition by Oculis Holding was on XXXXXXXX, XXXXX. Oculis Holding acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Oculis Holding
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialOculis Holding Investment Activity
Oculis Holding invested in XXX companies to date.
Oculis Holding made its latest investment on XXXXXXXX, XXXXX. Oculis Holding invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Oculis Holding
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Oculis Holding
| When was Oculis Holding founded? | Oculis Holding was founded in 2016. |
| Where is Oculis Holding headquartered? | Oculis Holding is headquartered in Switzerland. |
| How many employees does Oculis Holding have? | As of today, Oculis Holding has over 49 employees. |
| Who is the CEO of Oculis Holding? | Oculis Holding's CEO is Riad Sherif. |
| Is Oculis Holding publicly listed? | Yes, Oculis Holding is a public company listed on Nasdaq Iceland. |
| What is the stock symbol of Oculis Holding? | Oculis Holding trades under OCS ticker. |
| When did Oculis Holding go public? | Oculis Holding went public in 2024. |
| Who are competitors of Oculis Holding? | Oculis Holding main competitors are Samsung, Johnson & Johnson, Roche, Siemens. |
| What is the current revenue of Oculis Holding? | Oculis Holding's last 12 months revenue is $3M. |
| What is the current revenue growth of Oculis Holding? | Oculis Holding revenue growth (NTM/LTM) is 497%. |
| Is Oculis Holding profitable? | No, Oculis Holding is not profitable. |
| What is the current EBITDA of Oculis Holding? | Oculis Holding has negative EBITDA and is not profitable. |
| What is Oculis Holding's EBITDA margin? | Oculis Holding's last 12 months EBITDA margin is (3993%). |
| What is the current FCF of Oculis Holding? | Oculis Holding's last 12 months FCF is ($38M). |
| What is Oculis Holding's FCF margin? | Oculis Holding's last 12 months FCF margin is (1386%). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.